Evaluaciones económicas

Published on 29 de junio de 2018 | http://doi.org/10.5867/medwave.2018.03.7220

Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile

Back to article
Costs and benefits associated with Len/Dex and Bor/Dex treatment.